Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.51
CYTX's Cash to Debt is ranked lower than
87% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. CYTX: 0.51 )
Ranked among companies with meaningful Cash to Debt only.
CYTX' s Cash to Debt Range Over the Past 10 Years
Min: 0.3  Med: 4.60 Max: N/A
Current: 0.51
Equity to Asset 0.24
CYTX's Equity to Asset is ranked lower than
86% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CYTX: 0.24 )
Ranked among companies with meaningful Equity to Asset only.
CYTX' s Equity to Asset Range Over the Past 10 Years
Min: -0.83  Med: 0.12 Max: 0.94
Current: 0.24
-0.83
0.94
Interest Coverage 0.21
CYTX's Interest Coverage is ranked lower than
99% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYTX: 0.21 )
Ranked among companies with meaningful Interest Coverage only.
CYTX' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 0.21
F-Score: 5
Z-Score: -14.06
M-Score: 0.41
WACC vs ROIC
20.28%
11.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 5.02
CYTX's Operating margin (%) is ranked higher than
74% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. CYTX: 5.02 )
Ranked among companies with meaningful Operating margin (%) only.
CYTX' s Operating margin (%) Range Over the Past 10 Years
Min: -657.27  Med: -288.86 Max: -131.11
Current: 5.02
-657.27
-131.11
Net-margin (%) -17.37
CYTX's Net-margin (%) is ranked higher than
63% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. CYTX: -17.37 )
Ranked among companies with meaningful Net-margin (%) only.
CYTX' s Net-margin (%) Range Over the Past 10 Years
Min: -663.34  Med: -289.87 Max: -157.61
Current: -17.37
-663.34
-157.61
ROE (%) -264.70
CYTX's ROE (%) is ranked lower than
94% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. CYTX: -264.70 )
Ranked among companies with meaningful ROE (%) only.
CYTX' s ROE (%) Range Over the Past 10 Years
Min: -596.71  Med: -393.62 Max: -197.76
Current: -264.7
-596.71
-197.76
ROA (%) -5.40
CYTX's ROA (%) is ranked higher than
71% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. CYTX: -5.40 )
Ranked among companies with meaningful ROA (%) only.
CYTX' s ROA (%) Range Over the Past 10 Years
Min: -127.5  Med: -80.16 Max: -49.06
Current: -5.4
-127.5
-49.06
ROC (Joel Greenblatt) (%) 38.01
CYTX's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. CYTX: 38.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYTX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1689.33  Med: -1092.50 Max: -608.21
Current: 38.01
-1689.33
-608.21
Revenue Growth (3Y)(%) -30.50
CYTX's Revenue Growth (3Y)(%) is ranked lower than
77% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CYTX: -30.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYTX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -14.30 Max: 12.8
Current: -30.5
0
12.8
EBITDA Growth (3Y)(%) -40.30
CYTX's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CYTX: -40.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYTX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -40.3  Med: -16.20 Max: 37.6
Current: -40.3
-40.3
37.6
EPS Growth (3Y)(%) -37.00
CYTX's EPS Growth (3Y)(%) is ranked lower than
82% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CYTX: -37.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYTX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.5  Med: -13.60 Max: 102.9
Current: -37
-41.5
102.9
» CYTX's 10-Y Financials

Financials (Next Earnings Date: 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2014

CYTX Guru Trades in Q3 2014

Jim Simons 475,131 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2014

CYTX Guru Trades in Q4 2014

Jim Simons Sold Out
» More
Q2 2015

CYTX Guru Trades in Q2 2015

George Soros 22,400 sh (New)
» More
Q3 2015

CYTX Guru Trades in Q3 2015

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CBLI, NAS:ABIO, NAS:OGXI, AMEX:OGEN, NAS:SBOT, OTCPK:PRGB, NAS:CYAN, OTCPK:BNRPF, NAS:VTGN, OTCPK:PTGEF, NAS:CLSN, NAS:ICCC, NAS:OPXA, OTCPK:FENCF, AMEX:HEB, AMEX:CANF, NAS:VKTX, NAS:BLPH, NAS:HSGX, OTCPK:ANTB » details
Traded in other countries:XMPB.Germany,
Cytori Therapeutics Inc is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns.

Cytori Therapeutics Inc was incorporated in the State of Delaware in May 1997. The Company is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. Its core product is the Celution System, which extracts the naturally occurring ADRCs from a patient's own fat tissue and is CE Marked for a range of soft tissue procedures, including breast reconstruction. The company has completed three clinical trials using the Celution System for breast reconstruction, pipeline applications acute myocardial infarction, and chronic myocardial ischemia. It is involved in the European ADVANCE trial for acute myocardial infarction; and the U.S. trial for chronic myocardial ischemia. The company also sells StemSource cell banking line, including cell and tissue banking lines, as well as the Puregraft System that optimizes the fat graft preparation process. Its therapeutic areas comprises of cardiovascular disease, specifically refractory heart failure due to chronic myocardial ischemia, and the treatment of thermal burns. Its customers in Japan consist of researchers at academic hospitals and clinics. It also has a network of distributors who offer Celution Systems, instrumentation and consumables and Puregraft System to surgeons and hospitals throughout Europe. Celution Systems are or will be subject to stringent government regulation in the United States by the FDA under the Federal Food, Drug and Cosmetic Act.

Ratios

vs
industry
vs
history
P/B 3.75
CYTX's P/B is ranked lower than
53% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. CYTX: 3.75 )
Ranked among companies with meaningful P/B only.
CYTX' s P/B Range Over the Past 10 Years
Min: 2.12  Med: 32.02 Max: 797.32
Current: 3.75
2.12
797.32
P/S 1.89
CYTX's P/S is ranked higher than
90% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. CYTX: 1.89 )
Ranked among companies with meaningful P/S only.
CYTX' s P/S Range Over the Past 10 Years
Min: 1.56  Med: 12.11 Max: 42.53
Current: 1.89
1.56
42.53
EV-to-EBIT 44.92
CYTX's EV-to-EBIT is ranked lower than
73% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. CYTX: 44.92 )
Ranked among companies with meaningful EV-to-EBIT only.
CYTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -16  Med: -4.90 Max: 85.4
Current: 44.92
-16
85.4
EV-to-EBITDA 18.71
CYTX's EV-to-EBITDA is ranked higher than
50% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. CYTX: 18.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.5  Med: -5.30 Max: 35.6
Current: 18.71
-17.5
35.6
Current Ratio 1.71
CYTX's Current Ratio is ranked lower than
80% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CYTX: 1.71 )
Ranked among companies with meaningful Current Ratio only.
CYTX' s Current Ratio Range Over the Past 10 Years
Min: 1.01  Med: 3.17 Max: 26.46
Current: 1.71
1.01
26.46
Quick Ratio 1.24
CYTX's Quick Ratio is ranked lower than
83% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. CYTX: 1.24 )
Ranked among companies with meaningful Quick Ratio only.
CYTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 2.93 Max: 24.95
Current: 1.24
0.66
24.95
Days Inventory 510.38
CYTX's Days Inventory is ranked lower than
96% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. CYTX: 510.38 )
Ranked among companies with meaningful Days Inventory only.
CYTX' s Days Inventory Range Over the Past 10 Years
Min: 47.13  Med: 287.45 Max: 529.06
Current: 510.38
47.13
529.06
Days Sales Outstanding 24.74
CYTX's Days Sales Outstanding is ranked higher than
78% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. CYTX: 24.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.54  Med: 65.46 Max: 124.26
Current: 24.74
0.54
124.26
Days Payable 116.69
CYTX's Days Payable is ranked higher than
70% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. CYTX: 116.69 )
Ranked among companies with meaningful Days Payable only.
CYTX' s Days Payable Range Over the Past 10 Years
Min: 25.87  Med: 116.71 Max: 414.3
Current: 116.69
25.87
414.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.15
CYTX's Price/Median PS Value is ranked higher than
96% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CYTX: 0.15 )
Ranked among companies with meaningful Price/Median PS Value only.
CYTX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 1.01 Max: 3.47
Current: 0.15
0.18
3.47
Earnings Yield (Greenblatt) (%) 2.15
CYTX's Earnings Yield (Greenblatt) (%) is ranked higher than
81% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. CYTX: 2.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYTX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.2  Med: 1.90 Max: 2.4
Current: 2.15
1.2
2.4

More Statistics

Revenue (TTM) (Mil) $12.23
EPS (TTM) $ -0.06
Beta3.17
Short Percentage of Float3.37%
52-Week Range $1.91 - 7.93
Shares Outstanding (Mil)13.33

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 13 21 32
EPS ($) -1.92 -1.41 -13.97
EPS w/o NRI ($) -1.92 -1.41 -13.97
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CYTX

Headlines

Articles On GuruFocus.com
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 
5-year lows: Fuel Systems Solutions Inc, Dawson Geophysical Co, Forest Oil Corp, and Cytori Therapeu Sep 08 2014 
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: SSP, HPOL, CYTX, AGYS, VRX, TPI Mar 19 2012 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 09 2010 
Cytori Therapeutics Inc (CYTX) CFO Mark E Saad buys 6,000 Shares May 21 2010 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 10 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 6,600 Shares May 20 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 3,250 Shares May 19 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 7,000 Shares May 18 2009 

More From Other Websites
What Do All These Investigator-Initiated Studies Mean to Cytori? Jul 25 2016
Cytori to Webcast Second Quarter Financial Results on August 4 Jul 22 2016
Cytori to Webcast Second Quarter Financial Results on August 4 Jul 22 2016
ETF’s with exposure to Cytori Therapeutics, Inc. : July 19, 2016 Jul 19 2016
Cytori Cell Therapy™ Phase I Trial Reports Maxillofacial Bone Regeneration Jul 19 2016
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant,... Jul 14 2016
Cytori ATHENA Trial for Chronic Ischemic Cardiovascular Disease Jun 28 2016
Cytori ATHENA Trial for Chronic Ischemic Cardiovascular Disease Jun 28 2016
Cytori Cell Therapy Receives Limited Approval for Osteoarthritis in Japan Jun 27 2016
Cytori Cell Therapy Receives Limited Approval for Osteoarthritis in Japan Jun 27 2016
Cytori Cell Therapy Receives Limited Approval for Osteoarthritis in Japan Jun 27 2016
ETF’s with exposure to Cytori Therapeutics, Inc. : June 20, 2016 Jun 20 2016
CYTORI THERAPEUTICS, INC. Financials Jun 17 2016
Cytori Closes Rights Offering for Gross Proceeds of $17.1 Million Jun 15 2016
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 15 2016
Cytori Closes Rights Offering for Gross Proceeds of $17.1 Million Jun 15 2016
Cytori Announces Expiration of Rights Offering and Estimated Gross Proceeds of $17.1 Million Jun 13 2016
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jun 13 2016
Cytori Announces Expiration of Rights Offering and Estimated Gross Proceeds of $17.1 Million Jun 13 2016
Cytori Cell Therapy™ Leads to Improved Function and Reduced Scar Tissue in a Urinary Injury Model Jun 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)